US obesity rates may finally be falling, but weight-loss drugs are only part of the story

With more than a billion people living with obesity worldwide and weight-loss medications reshaping clinical care, leading experts examine what it will take to change the trajectory of one of the world's most pressing public health challenges.

Toward a Healthier Future Through Obesity Prevention and Care: The JAMA Summit Report on Obesity. Image Credit: Andrey_Popov / Shutterstock

In a recent special communication published in JAMA, a multidisciplinary group of clinicians, scientists, economists, policymakers, and patient advocates synthesized existing scientific evidence to outline a strategy to address the global obesity epidemic.

The report draws on scientific evidence and expert discussions at the May 2026 JAMA Summit on Obesity and examines the biological, socioeconomic, and environmental drivers of obesity. It also considers how newer medications and public health interventions could help reduce obesity prevalence and its associated health complications.

More than 50 international experts in obesity medicine, nutrition, public health, health policy, and patient advocacy prepared the report, representing institutions including the University of Pennsylvania, Harvard Medical School, Johns Hopkins University, the World Health Organization, and the World Obesity Federation.

Obesity now affects more than one billion people worldwide, with some estimates suggesting that obesity-related spending accounts for over 20% of healthcare costs in the United States (US).

The authors concluded that while newer anti-obesity medications offer substantial therapeutic benefits, addressing the ongoing obesity epidemic requires coordinated reforms across society targeting food environments, healthcare delivery, and pervasive weight stigma alongside expanded access to evidence-based treatments.

Background

The World Health Organization (WHO) defines obesity as abnormal or excessive fat accumulation that poses a health risk. In adults, obesity is commonly classified using a body mass index (BMI) of 30 kg/m² or greater, with lower thresholds used in some Asian populations. BMI is an indirect measure of body fat.

Decades of research have linked obesity to an increased risk of cardiovascular disease, type 2 diabetes, kidney and liver disease, and several cancers.

Changes in agricultural policies, aggressive food marketing, motorized transport, and sedentary screen time have contributed to an environment that promotes weight gain. Disrupted sleep and limited access to affordable, nutritious food may also contribute. Obesity disproportionately affects socioeconomically disadvantaged populations, even in high-income countries, where barriers to healthy eating, physical activity, and healthcare are often greater.

While historical public health initiatives have aimed to mitigate these risks, food and menu labeling have had modest benefits in isolation, school meal nutrition standards have shown benefits, and beverage taxes have produced mixed outcomes. Many programs have faced barriers to widespread implementation, including resistance from the commercial sector.

Traditional clinical biases have frequently framed obesity as a failure of an individual’s willpower rather than recognizing the biological and environmental factors that contribute to the disease. Such attitudes can erode patient trust and delay timely interventions.

A better understanding of the causes of obesity has informed clinical care, but integrating medical treatments with equitable public health policies remains challenging.

Obesity by the numbers: Findings from the JAMA Summit Report

Measure Value Scale (0% to 100%)
People with obesity living in low- and middle-income countries About 67%
US calorie intake from ultra-processed foods 55%
US children with obesity 1 in 5
US adults taking GLP-1 receptor agonists 1 in 9
Eligible patients undergoing metabolic or bariatric surgery Less than 1%

Note: Figures describe different populations and measures. Bars use a 0% to 100% scale. The surgery bar indicates an upper bound rather than an exact percentage. Source: Cappola AR, et al. JAMA (2026). doi:10.1001/jama.2026.19759

The JAMA Summit on Obesity

The report summarizes discussions from a multidisciplinary conference held in Chicago in May 2026. The meeting aimed to address fragmented prevention and treatment efforts by bringing together participants from clinical medicine, public health, economics, patient advocacy, government agencies, and the food, wellness, and pharmaceutical industries.

The participants discussed three areas: preventing obesity at the societal level, improving clinical care and access to evidence-based therapies, and advancing research to assess treatment outcomes beyond weight loss.

Understanding obesity and its evolving treatment options

National health data collected between 2021 and 2023 indicate that approximately two in five US adults and one in five children and adolescents had obesity. Globally, two-thirds of individuals living with obesity reside in low- and middle-income countries (LMICs).

Changes in US agricultural policies beginning in the 1970s increased food production, with daily calorie availability per person increasing from 3,200 to nearly 4,000 kilocalories. Ultra-processed foods (UPFs), often energy-dense, highly palatable, and inexpensive, accounted for about 55% of total US caloric intake between 2021 and 2023. Evidence regarding their contribution to rising obesity prevalence remains mixed.

The summit experts explained that physiological mechanisms (e.g., reduced energy expenditure and increased hunger signals) can resist weight loss and promote weight regain. Genetic and epigenetic factors influence individual susceptibility to obesity in environments that encourage excess calorie intake and sedentary behavior. Differences in metabolism among people living with obesity also support the need for personalized treatment.

Long-term observational research suggests that metabolic and bariatric surgery can increase life expectancy, yet fewer than 1% of eligible patients undergo surgical intervention, reflecting factors such as patient preferences and limited access to care.

The adoption of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has expanded clinical treatment options. These medications act on hormone receptors to reduce hunger and food cravings and increase satiety. Clinical trials have also documented benefits for cardiovascular, metabolic, kidney, and liver health in selected patient populations.

An estimated one in nine US adults is taking a GLP-1 RA. The authors suggest that widespread use of these treatments may be contributing to a decline in US obesity prevalence for the first time in decades, yet severe obesity continues to increase.

The experts caution that high costs, restrictive insurance approval requirements, gastrointestinal side effects, gallbladder disease, and high first-year discontinuation rates constrain these medications’ long-term public health benefits. Many patients may require ongoing treatment to maintain weight loss. The expanding online market for unapproved compounded alternatives and inadequately studied peptides raises further safety concerns.

Why obesity medications alone cannot curb the epidemic

The summit authors advocate treating obesity as a chronic disease with biological, behavioral, and environmental determinants. They reject the misconception that obesity stems from a lack of willpower. Medical treatment alone cannot address the underlying causes of rising obesity prevalence.

The authors propose that policymakers explore food packaging warning labels, restrictions on unhealthy food marketing to children, and stronger nutrition assistance programs (e.g., Supplemental Nutrition Assistance Program [SNAP]). Childhood obesity prevention, healthier school meals, and greater opportunities for physical activity are also priorities. The effectiveness of proposed measures requires further evaluation.

Other priorities include expanding insurance coverage and access to multidisciplinary care, training clinicians to provide weight-bias-free care, and supporting long-term treatment adherence. Future research should assess metabolic health, physical function, patient-centered outcomes, the benefits of combining surgery with medications, and the long-term safety and effectiveness of obesity treatments.

Several authors disclosed financial relationships with pharmaceutical companies, including Eli Lilly and Novo Nordisk. The AMA Foundation supported the organization of the summit.

Journal reference:
Hugo Francisco de Souza

Written by

Hugo Francisco de Souza

Hugo Francisco de Souza is a scientific writer based in Bangalore, Karnataka, India. His academic passions lie in biogeography, evolutionary biology, and herpetology. He is currently pursuing his Ph.D. from the Centre for Ecological Sciences, Indian Institute of Science, where he studies the origins, dispersal, and speciation of wetland-associated snakes. Hugo has received, amongst others, the DST-INSPIRE fellowship for his doctoral research and the Gold Medal from Pondicherry University for academic excellence during his Masters. His research has been published in high-impact peer-reviewed journals, including PLOS Neglected Tropical Diseases and Systematic Biology. When not working or writing, Hugo can be found consuming copious amounts of anime and manga, composing and making music with his bass guitar, shredding trails on his MTB, playing video games (he prefers the term ‘gaming’), or tinkering with all things tech.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Francisco de Souza, Hugo. (2026, November 18). US obesity rates may finally be falling, but weight-loss drugs are only part of the story. News-Medical. Retrieved on November 18, 2026 from https://www.news-medical.net/news/20261118/US-obesity-rates-may-finally-be-falling-but-weight-loss-drugs-are-only-part-of-the-story.aspx.

  • MLA

    Francisco de Souza, Hugo. "US obesity rates may finally be falling, but weight-loss drugs are only part of the story". News-Medical. 18 November 2026. <https://www.news-medical.net/news/20261118/US-obesity-rates-may-finally-be-falling-but-weight-loss-drugs-are-only-part-of-the-story.aspx>.

  • Chicago

    Francisco de Souza, Hugo. "US obesity rates may finally be falling, but weight-loss drugs are only part of the story". News-Medical. https://www.news-medical.net/news/20261118/US-obesity-rates-may-finally-be-falling-but-weight-loss-drugs-are-only-part-of-the-story.aspx. (accessed November 18, 2026).

  • Harvard

    Francisco de Souza, Hugo. 2026. US obesity rates may finally be falling, but weight-loss drugs are only part of the story. News-Medical, viewed 18 November 2026, https://www.news-medical.net/news/20261118/US-obesity-rates-may-finally-be-falling-but-weight-loss-drugs-are-only-part-of-the-story.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Immune cell differences may explain sex-specific obesity responses